Leukemia Clinical Trials in Arizona

Showing 361-380 of 1,229 trials

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

Mayo Clinic46 participantsStarted Aug 2025

Scottsdale, Arizona, United States • Rochester, Minnesota, United States

COMPLETEDPhase 231 miles

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Recurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma

Corcept Therapeutics178 participantsStarted Apr 2019

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Denver, Colorado, United States +21 more locations

PreviousPage 19 of 62Next

Q702 for the Treatment of Patients With Hematologic Malignancies

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Leukemia Trials in Other Cities

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

Epigenetic Reprogramming in Relapse/Refractory AML

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

A Study of Sovilnesib in Subjects With Ovarian Cancer

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Gilteritinib for the Treatment of ALK NSCLC

Other Conditions in Arizona